Solara Active Pharma Sciences Share News - Latest Updates, Live News & More

Latest news about Solara Active Pharma Sciences

Solara Active Pharma Sciences Reports Q2 Net Loss Amid Operational Challenges 3 days ago

Solara Active Pharma Sciences Ltd. reported a net loss of 101 million rupees in Q2, compared to a profit of 80 million rupees in the same period last year. Revenue decreased by 10% to 3.14 billion rupees, while EBITDA fell by 43% to 347.30 million rupees. The company attributed the decline to an unscheduled operational shutdown at its Mangalore facility for upgradation, leading to delayed deliveries and reduced sales volumes. Despite challenges, Solara maintained its focus on regulated markets, which accounted for 75% of total revenues. The company is working to reduce debt, which stood at 6,233 million rupees at the end of the quarter.

Solara Active Pharma Sciences Allots 8,040 Equity Shares Under Employee Stock Option Plan 3 days ago

Solara Active Pharma Sciences Announces Board Reshuffle, New CHRO Appointment, and Management Changes 3 days ago

Solara Active Pharma Sciences Reports Q2 Net Loss of 101M Rupees 3 days ago

Solara Active Pharma Sciences Receives Rs 4.88 Crore in First Call Money, Converts 3.71 Lakh Partly Paid-Up Shares Aug 16, 2025

More news about Solara Active Pharma Sciences

29Jul 25

Solara Active Pharma Sciences Reports Strong Q1 with 15% Revenue Growth and Highest PAT in 12 Quarters

Solara Active Pharma Sciences Limited reported robust Q1 results with revenue of INR 320.00 crores, up 15% quarter-on-quarter. EBITDA grew 13% quarter-on-quarter to INR 57.00 crores. The company achieved its highest PAT in 12 quarters at INR 10.50 crores. Debt was reduced by INR 143.00 crores, bringing the net debt-to-EBITDA ratio to 2.7x. Solara has reduced its dependence on ibuprofen to about 30% of business. The company is operating at 60-65% capacity utilization and expects 10% revenue growth and 15-20% EBITDA growth. Plans to demerge the CRAMS business are progressing, with expectations to grow this segment to INR 400.00-500.00 crores in 3-4 years.

25Jul 25

Solara Active Pharma Reports Strong Q1 Results with 15% Revenue Growth and Positive Earnings

Solara Active Pharma Sciences Limited has reported a strong financial performance for Q1, with revenue increasing by 15% QoQ to ₹319.15 crores. The company turned profitable with a net profit of ₹10.52 crores, compared to a loss of ₹13.46 crores in the same quarter last year. Gross margin improved by 960 bps YoY to 54.10%, while EBITDA margin rose by 640 bps YoY to 18.00%. The company's focus on regulated markets, cost control measures, and debt reduction contributed to this improved performance. Solara also appointed a new Chief Risk Officer and plans to raise ₹134.99 crores through pending rights issue calls.

06Jul 25

Solara Active Pharma Sciences Shifts Focus to High-Value Markets, Plans Demerger

Solara Active Pharma Sciences is shifting focus to high-value regulated markets, now contributing 76% of total business. The company plans to demerge its CRAMS and Polymers businesses into a new entity, Synthix Global Pharma Solutions. Despite challenges in FY25, Solara projects 10% revenue growth and 15-20% EBITDA growth for FY26. The company aims to reduce its net debt to EBITDA ratio to 1.70-1.80x by Q1 FY27.

15May 25

Solara Active Pharma Sciences Downgrades FY25 Financial Outlook

Solara Active Pharma Sciences has lowered its financial forecasts for FY25. The company now expects an EBITDA of ₹2.13 billion, down from the previous guidance of ₹2.30-2.60 billion. Revenue projections have also been reduced to ₹13.00 billion from over ₹15.00 billion. This downward revision suggests potential challenges in the company's growth trajectory and market conditions.

15May 25

Solara Active Pharma Sciences Reports Improved Q4 Performance Despite Revenue Dip

Solara Active Pharma Sciences Ltd. (SAPS) reported Q4 FY2024 results with a net loss of ₹200 crore, improved from ₹255 crore loss year-over-year. Revenue declined 9.70% to ₹270 crore. Q4 EBITDA was ₹59.20 crore with an improved Operating Profit Margin of 19.21%. Annual performance for FY24 showed challenges with revenue down 11.74% to ₹1,294.30 crore and a significant net loss of ₹567 crore.

12May 25

Solara Active Pharma's Ambernath Facility Passes USFDA Inspection with Flying Colors

Solara Active Pharma Sciences' Ambernath facility has successfully passed a United States Food and Drug Administration (USFDA) inspection without any Form 483 observations. This outcome indicates full compliance with USFDA's regulatory standards, potentially boosting the company's regulatory confidence, market reputation, and business opportunities in the U.S. pharmaceutical market. The clean inspection ensures operational continuity and reflects the high quality of Solara's manufacturing processes and compliance systems.

10May 25

Solara Active Pharma's Ambernath Facility Passes USFDA Inspection with Flying Colors

Solara Active Pharma Sciences Limited's Ambernath facility successfully completed a United States Food and Drug Administration (USFDA) inspection with no Form 483 observations. This outcome demonstrates the facility's compliance with stringent regulatory standards and could boost market confidence, potentially leading to expanded business opportunities in regulated markets, particularly the United States. The clean inspection report highlights Solara's commitment to maintaining high-quality manufacturing standards in the pharmaceutical industry.

24Feb 25

Solara Active Pharma Sciences to Shut Down Brazilian Subsidiary

Solara Active Pharma Sciences' board has approved the closure of its subsidiary in Brazil, Solara Active Pharma Sciences Ltda. This decision marks a significant shift in the company's international strategy, potentially impacting its operations in the South American market. The closure could lead to reduced operational costs, a shift in focus to other markets, and possible restructuring of the global supply chain. The move signals a strategic realignment for Solara, with potential implications for its financial performance and market position.

21Feb 25

Solara Active Pharma Sciences Announces Major Restructuring and Leadership Changes

Solara Active Pharma Sciences Limited has announced significant corporate changes following a board meeting on February 21, 2025. The company will close its non-operational Brazilian subsidiary. Key leadership appointments include Sandeep Rao as new MD & CEO, Sarat Kumar as CFO, and Vishal Mathur as CBO. The board approved granting 3,50,000 stock options to employees at Rs. 375 per option. Various committees have been reconstituted to reflect these changes.